Invasive Mucormycosis (IM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Mucormycosis has emerged as a notable infection within the contemporary post-COVID-19 period, significantly impacting morbidity and mortality rates. It is characterized by its affiliation with the zygomycete family and is categorized as an opportunistic fungal infection. This fungal pathogen is capable of inducing diverse forms of infections. Typically, the susceptibility to this infection is influenced by the host’s pre-existing health conditions. The fungi responsible for mucormycosis typically exist as benign environmental entities, causing no harm in individuals with intact immune systems. However, these otherwise innocuous organisms can become formidable and challenging opportunistic infections in immunosuppressed patients. Various clinical manifestations of mucormycosis include pulmonary, gastrointestinal, cutaneous, encephalic, and rhinocerebral presentations. The latter must be differentiated from allergic fungal sinusitis, a non-invasive, localized overgrowth observed in immunocompetent patients. The central feature of mucormycosis is the induction of tissue necrosis, facilitated by the invasion of blood vessels and subsequent thrombotic processes, often marked by swift progression. Mucormycosis represents an infectious malady stemming from fungi belonging to the class Zygomycetes and the order Mucorales. These Mucorales are prevalent in soil and decomposing matter. In individuals with intact immune systems, inhaled Mucorales spores adhere to nasal mucus and are expelled through swallowing or sneezing. In cases where mucous membrane wounds are present, polymorphonuclear neutrophils participate in the phagocytosis and destruction of fungal structures. Neutrophils play a pivotal role in host defense against these infections, rendering individuals with neutropenia or neutrophil dysfunction particularly vulnerable. The standard approach to managing mucormycosis necessitates timely diagnosis, mitigation of risk factors and underlying health issues, surgical removal of infected tissue, and expeditious administration of intravenous antifungal agents, often utilizing amphotericin B. When faced with rhinocerebral mucormycosis, differential diagnoses should include orbital cellulitis and cavernous sinus thrombosis. The prognosis hinges on the promptness of therapeutic intervention and the extent of underlying immunodeficiency in the patient, with mortality rates varying from 25% to 87%, depending on the infection site. Notable indicators of severity and poor prognosis encompass disseminated infection, central nervous system involvement, renal impairment, and inadequate response to medical treatment. The disease is associated with various complications, including cavernous sinus thrombosis, disseminated infection, periorbital destruction, osteomyelitis, and fatality. Treatment-related complications comprise nephrotoxicity, hypokalemia, and prolonged hospitalization, particularly in deoxycholate amphotericin B usage.
• Mucormycosis is a lethal opportunistic disease with a yearly incidence of 1.7 cases per one million population.

Thelansis’s “Invasive Mucormycosis (IM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Invasive Mucormycosis (IM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Invasive Mucormycosis (IM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Invasive Mucormycosis (IM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Invasive Mucormycosis (IM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Invasive Mucormycosis (IM), Invasive Mucormycosis (IM) market outlook, Invasive Mucormycosis (IM) competitive landscape, Invasive Mucormycosis (IM) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)